![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Peginterferon Lambda-1a (Lambda) Compared With Peginterferon Alfa-2a (Alfa) in
Treatment-Naive Patients With HCV Genotypes 1 or 4: SVR24 Results From EMERGE Phase 2b
|
|
|
Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
Muir A1 for the EMERGE Study Group; Hillson J,2 Gray T,2 Xu D,3 Ishak L,2
Freeman J,2 Fontana D,2 Horga A,3 Lopez-Talavera JC3
1Duke University Medical Center, Durham, NC; 2ZymoGenetics, Bristol-Myers Squibb, Seattle, WA; 3Research and Development, Bristol-Myers Squibb, Wallingford, CT
![AASLD1.gif](../images/111512/111512-6/AASLD1.gif)
![AASLD2.gif](../images/111512/111512-6/AASLD2.gif)
![AASLD3.gif](../images/111512/111512-6/AASLD3.gif)
![AASLD4.gif](../images/111512/111512-6/AASLD4.gif)
![AASLD5.gif](../images/111512/111512-6/AASLD5.gif)
![AASLD6.gif](../images/111512/111512-6/AASLD6.gif)
![AASLD7.gif](../images/111512/111512-6/AASLD7.gif)
![AASLD8.gif](../images/111512/111512-6/AASLD8.gif)
![AASLD9.gif](../images/111512/111512-6/AASLD9.gif)
![AASLD10.gif](../images/111512/111512-6/AASLD10.gif)
![AASLD11.gif](../images/111512/111512-6/AASLD11.gif)
![AASLD12.gif](../images/111512/111512-6/AASLD12.gif)
![AASLD13.gif](../images/111512/111512-6/AASLD13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|